Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)
David H. Henry(Pennsylvania Hospital), Kin-Hung P. Yu(First Affiliated Hospital of GuangXi Medical University), Gopal Saha(FibroGen (United States)), Moshe Mittelman(Tel Aviv University), Pamela Bartels(FibroGen (United States)), Robert Leong(FibroGen (United States)), Charles W. Bradley(FibroGen (United States)), Amy Zhou(University of Saskatchewan), John A. Glaspy(University of California, Los Angeles), Rosemary Harrup(University of Tasmania)
Cited by 23
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Cancer Detection with Whole-Body PET Using 2-[18F]Fluoro-2-Deoxy-D-Glucose
|Journal of Computer Assisted Tomography|1993|255